ASH 2023 Insights: "Clinical Outcomes Among Patients on Apixaban, Rivaroxaban, and Warfarin For AFib and/or VTE"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASH 2023 Insights: "Clinical Outcomes Among Patients on Apixaban, Rivaroxaban, and Warfarin For AFib and/or VTE"

By Insights from 2023 ASH Annual Meeting FEATURING Jordan Schaefer

0 views

December 17, 2023

Comments 0

Redefining the Treatment of Challenging Venous Occlusions with the V…

Feat. s. butty

Redefining the Treatment of Challenging Venous Occlusions with the V…

Feat. s. butty

COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Feat. S. Jain